Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Melanoma 68Carcinoma, Non-Small-Cell Lung 40Carcinoma, Renal Cell 36Neoplasm Metastasis 22Carcinoma, Hepatocellular 15Neoplasms 13Colorectal Neoplasms 13Brain Neoplasms 13Skin Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 10Lung Neoplasms 10Kidney Neoplasms 10Uveal Melanoma 9Ovarian Neoplasms 9Urinary Bladder Neoplasms 8Sarcoma 8Prostatic Neoplasms 8Carcinoma, Transitional Cell 8Mesothelioma 7Glioblastoma 7Clear-cell metastatic renal cell carcinoma 7Carcinoma, Merkel Cell 7Recurrence 6Colonic Neoplasms 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Mesothelioma, Malignant 5Carcinoma 5Stomach Neoplasms 4

Interventions

Proton Therapy 2Surgical Procedures, Operative 1Radiation Dose Hypofractionation 1Protons 1Nivolumab 1Neurosurgical Procedures 1Ipilimumab 1Dosage Forms 1Deamino Arginine Vasopressin 1Clinical Laboratory Techniques 1Cabergoline 1Blood Specimen Collection 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pituitary Neoplasms × Ipilimumab × 1 year × Clear all
NCT04042753 2026-06-02

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
10 enrolled
Endocrine

Pituitary Diseases, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡